Immunization with gp120-depleted whole killed HIV immunogen and a second-generation CpG DNA elicits strong HIV-specific responses in mice
| Autor: | Dorothy Bray, Lakshmi Bhagat, Alberto Clivio, Timothy Sullivan, Mario Clerici, Daria Trabattoni, Eugenio Cesana, Giada Maffeis, Richard Bartholomew, Ekambar R. Kandimalla, Francesca Lissoni, Silvia Beltrami, Peter Lowry, Sudhir Agrawal |
|---|---|
| Rok vydání: | 2006 |
| Předmět: |
Immunogen
animal diseases medicine.medical_treatment Oligonucleotides chemical and pharmacologic phenomena HIV Antibodies HIV Envelope Protein gp120 Virus Interferon-gamma Mice Immune system medicine Animals Lymphocytes HIV vaccine Chemokine CCL4 Chemokine CCL5 Cells Cultured Chemokine CCL3 AIDS Vaccines General Veterinary General Immunology and Microbiology biology Immunogenicity Public Health Environmental and Occupational Health virus diseases Macrophage Inflammatory Proteins bacterial infections and mycoses biology.organism_classification Virology Mice Inbred C57BL Infectious Diseases Lentivirus Immunology biology.protein Cytokines Molecular Medicine Drug Therapy Combination Female Interleukin-5 Antibody Adjuvant |
| Zdroj: | Vaccine. 24:1470-1477 |
| ISSN: | 0264-410X |
| DOI: | 10.1016/j.vaccine.2005.05.047 |
| Popis: | HIV-1 Immunogen is a gp120-depleted whole killed virus vaccine candidate formulated with Incomplete Freund's Adjuvant (HIV-IFA). We evaluated in a mouse model the immunogenicity of HIV-IFA by itself and when combined with HYB2055, an immunomodulatory oligonucleotide consisting of a novel DNA structure and synthetic CpR immunostimulatory motif, as an adjuvant. C57/BL6 mice were immunized with HIV-IFA alone or combined with HYB2055. Mice treated with HYB2055 or with PBS were used as controls. Compared to HIV-IFA alone, immunization with HIV-IFA and HYB2055 combination elicited strong production of HIV- and p24-specific IFNgamma, RANTES, MIP 1alpha, and MIP 1beta, as well as high titers of HIV- and p24-specific antibodies. Inclusion of HYB2055 also reduced levels of IL-5 produced by HIV-IFA alone. HYB2055 enhances the immunogenicity of HIV-IFA and shifts responses towards a type 1 cytokine profile. The immune enhancing effects of HYB2055 adjuvant were dose-dependent. These findings warrant clinical evaluation of the HIV-1 immunogen/HYB2055 candidate as a therapeutic vaccine for HIV-1 infected patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect